新藥物動向：疫苗 是由出版商Espicom Business Intelligence在2006年05月所出版的。
這份英文市場調查報告書包含48 PAGES 價格從美金1320起跳。
2005 年全球疫苗市場銷售超過 106 億美元，市場將由目前的平緩成長改為快速向前，預計 2010 年將擴充至接近 200 億美元左右。
提供醫療儀器、藥品相關情報，獲得全球高度評價的英國市調公司 Espicom Business Intelligence，調查分析了新疫苗後，出版了一本綜合報告書"New Drug Futures: Vaccines"。
報告書內容包括：市場動向、銷售變化、患者人口、目前治療概要、各企業概要、藥物詳細資訊等等，內容綱要摘記如下：
目前市場規模
患者人口
小兒用疫苗
成人用疫苗
子宮頸癌疫苗
肺癌疫苗
前列腺癌疫苗
銷售促進要素
銷售阻礙要素
未來治療
市場動向：勝方與敗方
2010 年前市場主要疫苗
評估基準
2010 年前主要疫苗
- Cervarix (GlaxoSmithKline/MedImmune)
- 新功能、效能
- 概念實證、臨床資料
- 管理與臨床專門性
- 市場競爭、市佔率獲取
- 治療層級中研發新藥物伴隨的風險
- 登錄與認可
- 銷售預測與假設
- 競爭公司分析
- Gardasil (Merck & Co/sanofi pasteur)
- 新功能、效能
- 概念實證、臨床資料
- 管理與臨床專門性
- 市場競爭、市佔率獲取
- 治療層級中研發新藥物伴隨的風險
- 登錄與認可
- 銷售預測與假設
- 競爭公司分析
- GVAX (Cell Genesys)
- 新功能、效能
- 概念實證、臨床資料
- 管理與臨床專門性
- 市場競爭、市佔率獲取
- 治療層級中研發新藥物伴隨的風險
- 登錄與認可
- 銷售預測與假設
- 競爭公司分析
- L-BLP25 (Biomira/Merck KGaA)
- 新功能、效能
- 概念實證、臨床資料
- 管理與臨床專門性
- 市場競爭、市佔率獲取
- 治療層級中研發新藥物伴隨的風險
- 登錄與認可
- 銷售預測與假設
- 競爭公司分析
- Provenge (Dendreon)
- 新功能、效能
- 概念實證、臨床資料
- 管理與臨床專門性
- 市場競爭、市佔率獲取
- 治療層級中研發新藥物伴隨的風險
- 登錄與認可
- 銷售預測與假設
- 競爭公司分析
- Rotarix (GlaxoSmithKline/Avant Immunotherapeutics)
- 新功能、效能
- 概念實證、臨床資料
- 管理與臨床專門性
- 市場競爭、市佔率獲取
- 治療層級中研發新藥物伴隨的風險
- 登錄與認可
- 銷售預測與假設
- 競爭公司分析
- Rotateq (Merck & Co.)
- 新功能、效能
- 概念實證、臨床資料
- 管理與臨床專門性
- 市場競爭、市佔率獲取
- 治療層級中研發新藥物伴隨的風險
- 登錄與認可
- 銷售預測與假設
- 競爭公司分析
- Streptorix (GlaxoSmithKline/MedImmune)
- 新功能、效能
- 概念實證、臨床資料
- 管理與臨床專門性
- 市場競爭、市佔率獲取
- 治療層級中研發新藥物伴隨的風險
- 登錄與認可
- 銷售預測與假設
- 競爭公司分析
- Zostavax (Merck & Co.)
- 新功能、效能
- 概念實證、臨床資料
- 管理與臨床專門性
- 市場競爭、市佔率獲取
- 治療層級中研發新藥物伴隨的風險
- 登錄與認可
- 銷售預測與假設
- 競爭公司分析
競爭公司分析：總結
競爭公司分析：疫苗
競爭公司分析：企業
Abstract
This chapter of New Drug Futures evaluates, compares and contrasts the
prospects for the compounds that will revolutionise the pharmaceutical
industry over the next 5 years and beyond in the vaccines sector. The report
includes unique sales forecasts by major product.
The full 400-page report, evaluates, compares and contrasts the prospects for
the compounds that will revolutionise the pharmaceutical industry over the
next 5 years and beyond. The report covers 8 key therapy areas
(alimentary/metabolic, anti-infectives, cancer, cardiovascular, CNS,
musculoskeletal, respiratory, vaccines) and includes unique sales forecasts by
major product. Click here for more information. This chapter is available
separately.
We estimate that vaccines generated sales of over US$10.6 billion in 2005,
with over 50% derived from traditional, domestic paediatric vaccines and the
development of novel vaccines that can command price premiums.
The market is beginning to turn around after a period of slow growth and it is
forecast to be worth nearly US$20 billion by 2010. Growth will be driven
principally by the adolescent and adult vaccine segment of the market as well
as the development of therapeutic vaccines.
The market has attracted the attention of eleven pharma players, with six of
these accounting for around 90% of vaccine sales by value.
Table of Contents
CURRENT MARKET SIZE
Vaccine Sales breakdown and forecasts
ADDRESSABLE PATIENT POPULATION
PAEDIATRIC VACCINES
ADULT VACCINES
CERVICAL CANCER VACCINES
LUNG CANCER VACCINES
PROSTATE CANCER VACCINES
CURRENT TREATMENTS
VACCINE SALES DRIVERS
VACCINE SALES BREAKERS
FUTURE TREATMENTS
MARKET DYNAMICS - WINNERS & LOSERS
KEY VACCINE LAUNCHES BY 2010
KEY EVALUATION CRITERIA
KEY VACCINE LAUNCHES BY 2010
- Cervarix (GlaxoSmithKline/MedImmune)
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management / clinical expertise
- Competition within the marketplace/gaining share of voice
- Risks associated with developing a drug within a therapeutic class
- Filings & Approvals
- Sales forecasts and assumptions
- Competitor Ratio Analysis
- Gardasil (Merck & Co/sanofi pasteur)
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management / clinical expertise
- Competition within the marketplace/gaining share of voice
- Risks associated with developing a drug within a therapeutic class
- Filings & Approvals
- Sales forecasts and assumptions
- Competitor Ratio Analysis
- GVAX (Cell Genesys)
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace/gaining share of voice
- Risks associated with developing a drug within a therapeutic class
- Filings and approval
- Sales forecasts and assumptions
- Competitor Ratio Analysis
- L-BLP25 (Biomira/Merck KGaA)
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace/gaining share of Voice
- Risks associated with developing a drug within a therapeutic class
- Filings & Approvals
- Sales forecasts and assumptions
- Competitor Ratio Analysis
- Provenge (Dendreon)
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace/gaining share of voice
- Risks associated with developing a drug within a therapeutic class
- Filings and approval
- Sales forecasts and assumptions
- Competitor Ratio Analysis
- Rotarix (GlaxoSmithKline/Avant Immunotherapeutics)
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management and clinical expertise
- Competition within the marketplace/ gaining share of voice
- Risks associated with developing a drug within a therapeutic class
- Filings & Approvals
- Sales forecasts and assumptions
- Competitor Ratio Analysis
- Rotateq (Merck & Co.)
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management and clinical expertise
- Competition within the marketplace/ gaining share of voice
- Risks associated with developing a drug within a therapeutic class
- Filings & Approvals
- Sales forecasts and assumptions
- Competitor Ratio Analysis
- Streptorix (GlaxoSmithKline/MedImmune)
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace/gaining share of voice
- Risks associated with developing a drug within a therapeutic class
- Filings and approval
- Sales forecasts and assumptions
- Competitor Ratio Analysis
- Zostavax (Merck & Co.)
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management / clinical expertise
- Competition within the marketplace/gaining share of voice
- Filings & Approvals
- Sales forecasts and assumptions
- Competitor Ratio Analysis
COMPETITOR RATIO ANALYSIS SUMMARY
COMPETITOR RATIO ANALYSIS - VACCINES
COMPETITOR RATIO ANALYSIS - COMPANIES
